Retatrutide Titration in Phase 3 Trials

In TRIUMPH-1, every participant on active treatment started at 2mg once weekly and escalated stepwise every four weeks to an assigned maintenance dose of 4mg, 9mg or 12mg. The number of steps differed by arm, which means the time spent climbing differed by arm, which in turn shapes how the 80-week results should be read.

Nothing here is a dosing recommendation. Retatrutide has no approval in any country, no brand name and no FDA Philippines registration. What follows is a description of what randomised trials did, in trial populations, under protocol, and it is not medical advice.

TRIUMPH-1 randomised 2,339 adults with obesity in a 1:1:1:1 ratio to 4mg, 9mg, 12mg or placebo, and ran 80 weeks with a further extension to 104. All three active arms began at 2mg once weekly and moved up stepwise every four weeks.

Step sequences and the four-week interval are as stated in the TRIUMPH-1 readout. The right-hand column is arithmetic on that four-week cadence rather than a separately published figure, and individual participants could deviate from the nominal schedule under protocol.

Two design features are worth naming. First, the shared 2mg start. Every active arm began identically, which keeps the early experience comparable across arms and protects the blind, since nobody can infer their assignment from the first injection. Second, the 6mg intermediate step, which exists only as a rung. It is not a maintenance dose in this trial. It appears in the 9mg and 12mg climbs and nowhere else, which is why quoting a 6mg retatrutide dose as a trial arm is a misreading.

If you search retatrutide titration you will mostly be shown a different trial. The 2023 Phase 2 study, published in the New England Journal of Medicine, enrolled 338 participants for 48 weeks and randomised them across seven groups: 1mg, 4mg from a 2mg start, 4mg from a 4mg start, 8mg from a 2mg start, 8mg from a 4mg start, 12mg from a 2mg start, and placebo.

That design is doing something specific and interesting. By running the same maintenance dose from two different starting doses, it tests the escalation itself rather than only the destination. Phase 2 is where a programme answers questions like that, and the answers feed into the Phase 3 design.

The practical consequence is that a large amount of currently published retatrutide dosing content describes doses that the pivotal trial does not use. There is no 8mg arm in TRIUMPH-1, and there is no 9mg arm in Phase 2. Searches for a comparison between 2mg, 4mg and 8mg are inherited from the older design. The current ladder in the trial that matters most is 4mg, 9mg and 12mg. The full readout by readout picture is in the TRIUMPH results filing.

Dose escalation is not caution for its own sake. It exists because of a specific, measured problem, and in this class the problem is gastrointestinal.

Across the TRIUMPH-1 arms, nausea ran 28.6% to 42.4%, diarrhoea 25.2% to 34.1% and constipation 23.8% to 26.1%. Vomiting was reported in 25.3% of the 12mg arm against 4.8% on placebo. Those are not marginal rates, and the pattern in this class is that these events cluster around exposure increases rather than persisting evenly for the whole trial.

That gives escalation two jobs. It spreads the exposure increase into smaller increments so each one is smaller in magnitude, and it puts a settling period between increments so that the transient peak in symptoms has time to subside before the next one arrives. A trial that started every participant at 12mg would face a wall of early dropouts and would tell you very little about what the dose does over 80 weeks, because too few people would still be in the trial to find out.

The second reason is pharmacokinetic and is covered above: with roughly a six-day half-life, exposure at any fixed dose keeps climbing for about four weeks. Stepping faster than that would mean stepping up while the previous step is still accumulating, so the effective exposure jump would be larger than the milligram jump on paper.

The reason TRIUMPH-1 is the most informative trial in the programme is that it ran the full ladder in one population under one protocol, which makes the comparison between arms a real comparison rather than an inference across studies.

Average body weight reduction at 80 weeks. The responder column is the proportion of participants reaching at least 30% reduction. Lilly also reported that 65.3% of the 12mg arm reached a BMI below 30.

Two different things are visible in that table. The average moves modestly across the ladder, from 19.0% to 28.3%. The responder proportion moves dramatically, from 15.3% to 45.3%. Dose is doing more to the shape of the distribution than to its centre, which is a more interesting finding than the headline average and one that almost no coverage of this trial mentions.

Here is the comparison that a page on titration exists to make, with nothing removed from either side of it.

The 4mg arm. One escalation step. At maintenance from roughly week four. Reported 19.0% average body weight reduction at 80 weeks, with 4.1% of participants discontinuing because of adverse events. That discontinuation rate is below the 4.9% recorded in the placebo arm.

The 12mg arm. Four escalation steps. At maintenance from roughly week sixteen. Reported 28.3% at 80 weeks, with 11.3% discontinuing because of adverse events, roughly two and a quarter times the placebo rate.

So the top of the ladder bought about nine additional percentage points of average weight reduction and roughly tripled the rate at which participants left the trial because they could not tolerate it. The 9mg arm sits between them on both measures: 25.9% and 6.9%.

The dysesthesia signal belongs in the same frame. TRIUMPH-4 reported it in 8.8% at 9mg and 20.9% at 12mg against 0.7% on placebo, and Lilly described the events as generally mild and rarely leading to discontinuation. It did not appear in the Phase 2 literature at all, which is exactly why pages built on the Phase 2 design do not mention it. It is covered in the dysesthesia filing with the wider tolerability picture in the safety filing.

Look at the increments rather than the levels and the shape of the dose response becomes the most useful thing in the dataset.

From 4mg to 9mg, average weight reduction moves from 19.0% to 25.9%, a step of roughly seven percentage points, while discontinuation for adverse events moves from 4.1% to 6.9%. From 9mg to 12mg, weight reduction moves from 25.9% to 28.3%, a step of roughly two and a half points, while discontinuation moves from 6.9% to 11.3%.

The efficacy curve is flattening across the top of the ladder while the tolerability curve is steepening. That is a classic dose-response shape and it is the reason a trial runs multiple maintenance arms rather than one: to find where the two curves cross for different purposes. It is also why a regulator reviewing this programme will be looking at more than the highest number in it.

The counterweight is the responder distribution. On averages, 12mg looks like a small increment over 9mg. On the proportion reaching 30% or more reduction, it is 45.3% against 37.9%, and on reaching a BMI below 30 the 12mg figure is 65.3%. For a trial population where those thresholds matter, the top of the ladder is not purchasing a rounding error.

TRIUMPH-1 is the trial with the published escalation detail. The rest of the programme is consistent with it but is not described at the same resolution in the public releases, and this page will not invent the missing detail.

What is on the record: TRIUMPH-4, the first Phase 3 readout, reported 9mg and 12mg arms in an obesity plus knee osteoarthritis population over 68 weeks, at 26.4% and 28.7% respectively. TRIUMPH-2 reported 20.8% at 12mg over 80 weeks in type 2 diabetes alongside an A1C reduction of 1.6%. TRIUMPH-3 reported 22.6% at 12mg over 80 weeks in severe obesity with established cardiovascular disease. Across the programme, the maintenance doses carried into Phase 3 are 4mg, 9mg and 12mg.

Three trials have not reported. TRIUMPH-5 puts retatrutide against tirzepatide in a single protocol, TRIUMPH-6 addresses weight maintenance, and TRIUMPH-OUTCOMES is a cardiovascular and renal outcomes trial in roughly 10,000 participants. TRIUMPH-6 is the one most relevant to this page, because maintenance is the question of what happens to the schedule after the climb ends.

On the regulatory side, Lilly stated on 23 July 2026 that it plans to submit a Biologics License Application to the US FDA in Q1 2027. Until a regulator reviews and approves a label, no titration schedule for retatrutide is an approved one, anywhere.

Everything above describes a randomised controlled trial. The distance between that and a reader following the same numbers is larger than it looks, and it is worth spelling out.

• Participants were screened for eligibility and exclusion criteria before any dose was given.
• Escalation happened under investigator supervision, with the ability to pause, hold or stop a step in response to what was actually happening to a participant.
• The compound used was a manufactured investigational product with a known concentration and a controlled supply chain.
• Adverse events were captured systematically rather than noticed, and discontinuation was a recorded outcome rather than a private decision.
• A quarter of the 12mg arm reported vomiting, and 11.3% left the trial for adverse events, with all of that support in place.

The country context and access picture sit in the retatrutide Philippines filing, with the regulatory background in the FDA Philippines guide. The reconstitution calculator works in trial units for the same reason this page does.

1. [01]TrialLilly · TRIUMPH-1 pivotal readout, 21 May 2026

   Source for the 2mg start, the four-week stepwise escalation and the per-arm step sequences, plus weight reduction, responder proportions and discontinuation rates at 4mg, 9mg and 12mg.

   investor.lilly.com · TRIUMPH-1 release
2. [02]TrialLilly · Phase 2 results published in NEJM, June 2023

   Source for the seven Phase 2 randomised groups, including both starting doses tested and the 8mg maintenance groups that do not appear in TRIUMPH-1.

   investor.lilly.com · Phase 2 release
3. [03]TrialNEJM 2023 · Retatrutide Phase 2 obesity trial

   Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, a Phase 2 trial. N Engl J Med 2023;389:514-526.

   https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
4. [04]TrialLilly · TRIUMPH-2 and TRIUMPH-3 readout, 23 July 2026

   Results in type 2 diabetes and in severe obesity with cardiovascular disease, plus the Q1 2027 BLA statement quoted in section 08.

   investor.lilly.com · TRIUMPH-2 and TRIUMPH-3 release
5. [05]PharmacokineticsUrva S et al. The Lancet 2022

   Phase 1b multiple ascending dose trial. Lancet 2022;400:1869-1881. Source of the approximately six-day half-life underlying the four-week step interval.

   Lancet 2022;400:1869-1881